Last updated: February 17, 2026
Product Overview
NDC 59762-0119 corresponds to Kalydeco (ivacaftor), a medication indicated for cystic fibrosis in patients with specific CFTR gene mutations. Approved by the FDA in 2012 and developed by Vertex Pharmaceuticals, ivacaftor has become a key therapy for cystic fibrosis with certain genetic profiles.
Market Size and Demand Drivers
-
Patient Population: Estimates place cystic fibrosis (CF) prevalence at approximately 70,000 patients in the U.S. (Cystic Fibrosis Foundation, 2022). About 12% of CF patients carry the G551D mutation, which ivacaftor targets, translating to roughly 8,400 eligible patients in the U.S.
-
Global Reach: The European CF population is estimated at 20,000, with similar mutation distribution, expanding the market scope beyond North America.
-
Treatment Penetration: As of 2022, approximately 60% of eligible patients in the U.S. receive ivacaftor, influenced by pricing, insurance coverage, and drug approval for additional mutations.
Market Dynamics
-
Competitive Landscape: Kalydeco competes mainly with other CFTR modulators, including Orkambi (lumacaftor/ivacaftor) and Trikafta (elexacaftor/tezacaftor/ivacaftor). Trikafta, approved in 2019, extends coverage to a broader patient base and has captured significant market share.
-
Revenue Streams: Vertex reported revenues of approximately $3.8 billion in 2022 for CF franchise products, with ivacaftor comprising a substantial segment, though declining post-Trikafta’s introduction.
-
Pricing: List prices for Kalydeco hover around $30,000 per month with significant variation based on negotiation and insurance coverages. Discounting and negotiations reduce actual net prices.
Pricing Trends and Projections
-
Current Price: Approximately $30,000/month (~$360,000/year) per patient in the U.S.
-
Historical Trends: List prices increased by roughly 8% annually since FDA approval, aligned with inflation-adjusted drug costs and sustained demand.
-
Future Price Projections:
| Year |
Estimated Average Price (USD/month) |
Notes |
| 2023 |
$30,000 |
Current price |
| 2025 |
$32,500 |
Assumes 8-9% annual increase |
| 2030 |
$37,500 |
Continued inflation, market stability |
Note: Actual net prices may be lower due to rebates, discounts, and insurance negotiations.
Forecasted Market Share
-
Market Penetration: Expected to decline gradually as Trikafta expands coverage. Estimates suggest ivacaftor’s share of the CFTR modulator market drops from 60% in 2022 to approximately 40% by 2030.
-
Revenue Impact: Reduced market share mitigated by increasing treatment duration and expanding indications; total revenues may stabilize around $2.5-$3 billion annually.
Uncertainties and Risk Factors
-
Regulatory Updates: Potential approvals for additional CFTR mutations could expand the eligible population, sustaining demand.
-
Pricing Pressures: Payer negotiations and societal cost containment measures could limit price growth.
-
Competitive Developments: Development of generics or biosimilars remains unlikely in the short term due to patent exclusivity, but future patent cliffs could impact prices post-2030.
Summary of Key Data
| Metric |
2022 |
2023 |
2025 |
2030 |
| Patient Population (U.S.) |
8,400 |
8,500 |
8,600 |
8,700 |
| List Price per Month |
$30,000 |
$30,000 |
$32,500 |
$37,500 |
| Estimated Market Share |
60% |
55% |
45% |
40% |
| Estimated Annual Revenue |
~$2.5B |
~$2.7B |
~$2.8B |
~$3.0B |
Conclusion
While ivacaftor’s market remains sizable within its niche, continued competition from newer CFTR modulators reduces its dominance. Price growth aligns with inflation and demand stability but faces downward pressure from payer negotiations and expanded market access via Trikafta. Long-term revenue will depend heavily on indications expansion and competitive landscape evolution.
Key Takeaways
-
The immediate market for ivacaftor is confined to a limited patient group, but revenues remain substantial due to high pricing and treatment longevity.
-
The introduction of Trikafta has markedly shifted market share, prompting a decline in ivacaftor’s relative size.
-
Price projections suggest steady growth, influenced by inflation and market dynamics, with potential stabilization or decline contingent on pricing policies and competition.
-
Future approvals for additional mutations could expand the market, offsetting declines elsewhere.
-
Significant uncertainties include payer negotiations, regulatory changes, and the pace of innovation in CF therapy.
FAQs
-
What is the current global market size for ivacaftor?
Estimated at around $3.5 billion annually, combining North American and European markets.
-
How does Trikafta impact the demand for Kalydeco?
Trikafta covers a broader patient group and has overshadowed Kalydeco, reducing its market share.
-
Are prices likely to rise or fall in the next five years?
Prices are projected to increase modestly, aligned with inflation, but actual net prices may be lower due to discounts.
-
Could generic or biosimilar versions threaten ivacaftor?
Extensive patent protection makes generics unlikely in the near term; patent cliffs could pose risks after 2030.
-
What factors could alter projections significantly?
Regulatory approvals, new treatment guidelines, pricing reforms, and competitive innovations.
Cited Sources
[1] Cystic Fibrosis Foundation. "2022 Patient Registry Annual Data Report."
[2] Vertex Pharmaceuticals. Annual Reports 2022.
[3] FDA. Drug Approval Package for Ivacaftor, 2012.
[4] EvaluatePharma. "Pharmaceutical Market Estimates," 2022.
